https://scholars.lib.ntu.edu.tw/handle/123456789/530168
標題: | The gestational effect of antenatal corticosteroids on respiratory distress syndrome in very low birth weight infants: A population-based study | 作者: | Liu S.-Y. Yang H.-I. CHIEN-YI CHEN HUNG-CHIEH CHOU Hsieh W.-S. Tsou K.-I. PO-NIEN TSAO Hsu C.-H. Mu S.-C. Lin J.-Y. Lin H.-C. Huang C.-C. Hsieh K.-S. Taiwan Premature Infant Follow-up Network |
公開日期: | 2020 | 出版社: | Elsevier B.V. | 卷: | 119 | 期: | 8 | 起(迄)頁: | 1267-1273 | 來源出版物: | Journal of the Formosan Medical Association | 摘要: | Background/Purpose: The aim of this study was to evaluate the efficacy of antenatal corticosteroids for preventing very low birth weight (VLBW) infants with respiratory distress syndrome (RDS) from surfactant use at different gestational ages (GA). Methods: We retrospectively analyzed the VLBW preterm infants registered in the Premature Baby Foundation of Taiwan from 1997 through 2014. Infants at 20–37 weeks' gestation were included, and infants with lethal congenital anomaly, chromosomal anomaly, and congenital infection were excluded. Antenatal corticosteroid courses were classified into two groups (<2 doses or ≧2 doses). The beneficial effect of antenatal corticosteroids on preventing VLBW infants with RDS from surfactant use was evaluated according to gestational ages. Results: Total 12,685 VLBW infants were included. For VLBW infants with gestational age 26–33 weeks, antenatal corticosteroid therapy has significantly protective effect (odds ratio 0.43 [95% CI 0.26 to 0.72] - 0.60 [95% CI 0.48 to 0.75], P < 0.05). The effect was not obvious for VLBW infants with gestational age 34 weeks and more (odds ratio 0.32 [95% CI 0.08 to 1.38], P = 0.127). Conclusion: For VLBW infants with RDS at 34 weeks' gestation and more, the beneficial effect of antenatal corticosteroids on preventing surfactant use was not evident. In conclusion, completion of two doses or more of antenatal corticosteroids is of great importance for VLBW infants with RDS at gestational age between 26 and 33 weeks on preventing surfactant use. ? 2019 Formosan Medical Association |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85076535866&doi=10.1016%2fj.jfma.2019.11.002&partnerID=40&md5=b38cc8c38a07317a4630d7f82431c08f https://scholars.lib.ntu.edu.tw/handle/123456789/530168 |
ISSN: | 0929-6646 | DOI: | 10.1016/j.jfma.2019.11.002 | SDG/關鍵字: | beractant; betamethasone; corticosteroid; dexamethasone; corticosteroid; surfactant; Article; corticosteroid therapy; disease association; drug efficacy; gestational age; human; infant; major clinical study; neonatal respiratory distress syndrome; prematurity; retrospective study; Taiwan; very low birth weight; birth weight; epidemiology; female; gestational age; neonatal respiratory distress syndrome; newborn; pregnancy; prematurity; Adrenal Cortex Hormones; Birth Weight; Female; Gestational Age; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Very Low Birth Weight; Pregnancy; Respiratory Distress Syndrome, Newborn; Retrospective Studies; Surface-Active Agents; Taiwan |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。